Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Debt Repayments (2019 - 2024)

Sutro Biopharma (STRO) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $4.1 million as the latest value for Q1 2024.

  • Quarterly Long-Term Debt Repayments rose 30.66% to $4.1 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2024, down 67.34% year-over-year, with the annual reading at $4.1 million for FY2024, 67.34% down from the prior year.
  • Long-Term Debt Repayments hit $4.1 million in Q1 2024 for Sutro Biopharma, up from $3.1 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $10.0 million in Q1 2020 to a low of $3.1 million in Q3 2022.
  • Historically, Long-Term Debt Repayments has averaged $4.1 million across 4 years, with a median of $3.1 million in 2022.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 1900.0% in 2020 and later changed 0.0% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $10.0 million in 2020, then crashed by 68.75% to $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then surged by 30.66% to $4.1 million in 2024.
  • Business Quant data shows Long-Term Debt Repayments for STRO at $4.1 million in Q1 2024, $3.1 million in Q4 2023, and $3.1 million in Q3 2023.